OSE Immunotherapeutics Shares Bounce Back at Close After Ambitious Strategic Plan
Shares of the Nantes-based biotechnology company OSE Immunotherapeutics rose by 4.81% on Wednesday to close at 5.01 euros, buoyed by the presentation of a three-year strategic roadmap. This rebound follows several weeks of decline and marks a pause in a long-term unfavorable trend.
Unveiling of a New Three-Year Strategic Plan
OSE Immunotherapeutics unveiled its new three-year strategic plan on Monday, December 9th, aimed at accelerating the development of its most promising programs while maintaining strict financial discipline. The 4.81% increase from 4.78 euros the previous day brought the share price to 5.01 euros, with a traded capital share of 0.67%. However, the movement is part of a negative medium-term dynamic: the stock is still down 4.3% over the week and 18.2% over three months. Over one year, the loss reaches 37.14%, reflecting the uncertainties of the biotechnological sector. Technically, OSE Immunotherapeutics now fluctuates between a support at 4.78 euros and a resistance at 6.03 euros. The stock is below its 50-day and 200-day moving averages, at 5.84 and 5.86 euros respectively, confirming a fundamental bearish trend. The Relative Strength Index (RSI) stands at 13, an extreme oversold level suggesting a potential short-term technical rebound. This configuration indicates an overreaction to the downside that could give way to a recovery, as observed this Wednesday.
Amendment to Partnership Agreement with AbbVie
On December 8th, OSE Immunotherapeutics announced an amendment to its partnership agreement with AbbVie on ABBV-230, a preclinical phase monoclonal antibody, taking back control of early development while AbbVie retains its rights to lead future development and commercialization of the product after successful Phase 1 clinical trials. With this amendment, OSE Immunotherapeutics will no longer receive the previously anticipated milestone payment related to the initiation of a Phase 1 clinical study, which initially weighed on the stock price. This adjustment is part of the new strategy unveiled the following day. The plan includes the completion of the pivotal Phase 3 trial of Tedopi in non-small cell lung cancer, with a futility analysis expected in the third quarter of 2026 and full results in the first quarter of 2028, all requiring limited financial resources. The company has financial visibility until the beginning of the fourth quarter of 2026, excluding additional funding or milestone payments, although the three-year strategic plan requires significantly less investment than initially planned.
Bearish Technical Indicators Persist
The MACD (Moving Average Convergence Divergence) of OSE Immunotherapeutics shows a bearish configuration, with a MACD line at -0.22 below its signal line at -0.18, generating a negative histogram of -0.04. This divergence confirms the dominant selling pressure on the stock over the past several weeks. However, the RSI at 13 signals an excess of pessimism that could trigger a technical correction movement, as evidenced by Wednesday's session. The one-month volatility stands at 7.92%, a high level for a biotechnological value in strategic restructuring. The near-zero beta (-0.01) indicates a low correlation with the overall market, typical of biotechnology companies in clinical development. The Bollinger Bands, ranging from 4.80 euros (lower band) to 5.81 euros (upper band), frame a narrow range where the stock is currently trading above the low threshold, suggesting a potential continuation of the upward trend towards the 5.80 euros area if the rebound is confirmed. The Scholes indicator generates a buy signal, consistent with the observed oversold level.
